 If GSK PLC LSE:GSK, NYSE:GSK GSK PLC LSE:GSK, NYSE:GSK, GSK PLC LSE:GSK, NYSE:GSK hoped spinning off its consumer household arm Haleon in July would lead to an instant re-rating to a supercharged US pharma level, it must be sorely disappointed so far. Shares have barely moved either way since the separation, but next weeks results should give a clearer picture of where new GSK sits in the pharma league table as explored more fully in the GSK preview. 